The global antiviral drugs market is anticipated to grow at a CAGR of around 3.7% during the forecast period 2020 to 2027 and to reach around US$ 74.7 Bn by 2027.
Market Dynamics
Substantial increase in number of patients suffering from viral infections and increasing R&D activities by major players for development of novel products are major factors expected to drive the growth of global antiviral drugs market. In US the proportion of outpatient visits for influenza-like illness increased slightly to 1.7 percent, which is below the national baseline of 2.2 percent. There is substantial increase in inpatients in hospitals for treatment of infections. According to U.S. Department of Health & Human Services, from October 2019, through April 4, 2020, there was 410,000-740,000 hospitalization related to flu and 24,000-62,000 deaths due to flu. According to World Health Organization, an estimated 491.5 million people were living with HSV-2 infection in 2016, equivalent to 13.2% of the world’s population aged 15 to 49 years. Increase in pandemic effect across the globe and rise in mortality rate are pressurizing the government to take necessary steps for drug development. Major players are focused on conducting rapid clinical trials for development of new drug, along with early product approval from the government as a preventive measure for treatment of covid-19 patients are factors cumulatively expected to augment the market growth. In 2020, the U.S. Food and Drug Administration granted full approval to the antiviral drug remdesivir as a treatment for patients hospitalized with COVID-19.
High investment by major players for new drug development and business development activities in order to enhance the business presence and increase the customer base is expected to boost the growth of antiviral drugs market.
In 2020, Glenmark Pharmaceuticals, a drug manufacturing company, launched its Favipiravir with brand name “FabiFlu” in the Indian market for treatment of covid-19. The company received approval from Drug Controller General of India (DCGI) for marketing and selling of the drug in the market.
In 2020, Cipla a global pharmaceutical company launched Favipiravir a Covid-19 drug for treatment of patients range especially in mild and moderate cases.
NeuroBo Pharmaceuticals, Inc. a clinical-stage biotechnology company acquired ANA Therapeutics, a privately held biotechnology company in 2021. The company is focused on developing ANA-001a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. This acquisition is expected to help the company to enhance the business and increase the customer base.
Factors such as high cost of R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global antiviral drugs market. In addition, presence of generic drugs is expected to challenge the growth of target market. However, increasing investment by major players for cost effective drug development and supporting government regulations related to product approval and business establishment are factors expected to create new opportunities for players operating in the antiviral drugs market. In addition, increasing partnership and agreements between regional and international players is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global drugs market due to rise in number of patients suffering from chronic diseases. In addition, availability of advanced infrastructure in the country, increasing R&D activities, and focus on introduction of innovative drugs are factors expected to impact the growth of antiviral drugs market. Rise in business development activities through acquisitions and partnerships is expected to augment the regional market growth.
The market in Asia pacific is expected to witness faster growth in the antiviral drugs market due to increasing government spending on development of healthcare infrastructure. Favorable business policies by the government and focus on strengthening the regional manufacturing capabilities are factors expected to augment the regional market growth. In addition, government focus on development of hospital infrastructure in order to deliver enhanced care is expected to support the growth of antiviral drugs market.
Competitive Landscape
The global antiviral drugs market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Report coverage
|
Market
|
Global Antiviral Drugs Market
|
|
Analysis Period
|
2016 – 2027
|
|
Base Year
|
2019
|
|
Forecast Data
|
2020 – 2027
|
|
Market Stratification
|
Type, Drug Class, Application and Geography
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling,
Regulation Analysis
|
Antiviral Drugs Market Segment Analysis, 2019
The global antiviral drugs market is segmented into type, drug class, and application. The drug class segment is bifurcated into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. Among drug class, the reverse transcriptase inhibitors segment is expected to account for a major revenue share in the global antiviral drugs market. The application segment is divided into HIV, hepatitis, herpes, influenza, and others. Among applications, the HIV segment is expected to account for a noticeable revenue share in the global market. Players operating in the global antiviral drugs market are Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, and Dr. Reddy’s Laboratories Ltd.
Market Segmentation
Market By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
Market By Type
Branded
Generic
Market By Application
HIV
Hepatitis
Herpes
Influenza
Others
Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Antiviral Drugs
1.1. Definition and Scope
1.1.1. Definition of Antiviral Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Antiviral Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Antiviral Drugs Market By Type
1.2.3. Antiviral Drugs Market By Drug Class
1.2.4. Antiviral Drugs Market By Application
1.2.5. Antiviral Drugs Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Antiviral Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Antiviral Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Proportion of Manufacturing Cost Structure
3.8.1.1. Raw Material
3.8.1.2. Labor Cost
3.8.1.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Antiviral Drugs Major Manufacturers in 2019
CHAPTER 5. Antiviral Drugs Market By Type
5.1. Introduction
5.2. Antiviral Drugs Revenue By Type
5.2.1. Antiviral Drugs Revenue (US$ Mn) and Forecast, By Type, 2016-2027
5.2.2. Branded
5.2.2.1. Branded Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Generic
5.2.3.1. Generic Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Antiviral Drugs Market Revenue By Drug Class
6.1. Introduction
6.2. Antiviral Drugs Revenue (US$ Mn) By Drug Class
6.2.1. Antiviral Drugs Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
6.2.2. DNA Polymerase Inhibitors
6.2.2.1. DNA Polymerase Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Reverse Transcriptase Inhibitors
6.2.3.1. Reverse Transcriptase Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Protease Inhibitors
6.2.4.1. Protease Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Neuraminidase Inhibitors
6.2.5.1. Neuraminidase Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.6. Others
6.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Antiviral Drugs Market By Application
7.1. Introduction
7.2. Antiviral Drugs Revenue (US$ Mn) By Application
7.2.1. Antiviral Drugs Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.2.2. HIV
7.2.2.1. HIV Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Hepatitis
7.2.3.1. Hepatitis Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Herpes
7.2.4.1. Herpes Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.5. Influenza
7.2.5.1. Influenza Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.6. Others
7.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Antiviral Drugs Market By Country
8.1. North America Antiviral Drugs Overview
8.2. U.S.
8.2.1. U.S. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.2. U.S. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.2.3. U.S. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.3. Canada
8.3.1. Canada Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.2. Canada Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.3.3. Canada Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Antiviral Drugs Market By Country
9.1. Europe Antiviral Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.2.2. U.K. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.2.3. U.K. Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.3. Germany
9.3.1. Germany Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.3.2. Germany Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.3.3. Germany Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.4. France
9.4.1. France Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.4.2. France Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.4.3. France Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.5. Spain
9.5.1. Spain Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.5.2. Spain Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.5.3. Spain Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.6.2. Rest of Europe Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.6.3. Rest of Europe Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Antiviral Drugs Market By Country
10.1. Asia Pacific Antiviral Drugs Market Overview
10.2. China
10.2.1. China Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.2.2. China Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.2.3. China Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.3. Japan
10.3.1. Japan Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.3.2. Japan Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.3.3. Japan Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.4. India
10.4.1. India Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.4.2. India Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.4.3. India Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.5. Australia
10.5.1. Australia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.5.2. Australia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.5.3. Australia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.6.2. South Korea Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.6.3. South Korea Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.7.2. Rest of Asia-Pacific Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.7.3. Rest of Asia-Pacific Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Antiviral Drugs Market By Country
11.1. Latin America Antiviral Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.2.2. Brazil Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.2.3. Brazil Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.3.2. Mexico Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.3.3. Mexico Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.4.2. Rest of Latin America Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 – 2027
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Antiviral Drugs Market By Country
12.1. Middle East & Africa Antiviral Drugs Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.2.2. Saudi Arabia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.2.3. Saudi Arabia Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.3. UAE
12.3.1. UAE Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.3.2. UAE Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.3.3. UAE Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.4.2. Rest of Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.4.3. Rest of Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. PLAYER ANALYSIS OF ANTIVIRAL DRUGS
13.1. Antiviral Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Antiviral Drugs Market
CHAPTER 14. COMPANY PROFILE
14.1. Gilead Sciences
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. Gilead Sciences 2019 Antiviral Drugs Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Manufacturing Plant Footprint Analysis
14.2. F. Hoffmann-La Roche AG
14.3. GlaxoSmithKline plc
14.4. AbbVie
14.5. Merck & Co., Inc.
14.6. Johnson & Johnson Services, Inc.
14.7. Bristol-Myers Squibb Company
14.8. Cipla Inc.
14.9. Aurobindo Pharma
14.10. Dr. Reddy’s Laboratories Ltd.
14.11. Others
